Cargando…

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

Detalles Bibliográficos
Autores principales:	Ashby, J, Garvey, LJ, Erlwein, OW, Lamba, H, Weston, R, Legg, K, McClure, MO, Dickinson, L, D'Avolio, A, Back, DJ, Winston, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112847/ http://dx.doi.org/10.1186/1758-2652-13-S4-O33

Ejemplares similares

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
por: Smirne, Carlo, et al.
Publicado: (2021)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study
por: Gurjar, Rohan, et al.
Publicado: (2022)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers
por: Barroso, Sergio, et al.
Publicado: (2019)

DNA Extraction Columns Contaminated with Murine Sequences
por: Erlwein, Otto, et al.
Publicado: (2011)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
por: Siccardi, M, et al.
Publicado: (2010)

The ICU Bridge Program: volunteers bridging medicine and people together
por: Petrecca, Sarah, et al.
Publicado: (2022)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Raltegravir: molecular basis of its mechanism of action
por: Mouscadet, Jean-François, et al.
Publicado: (2009)

886. Pregnancy Outcomes Following Raltegravir Exposure
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome
por: Erlwein, Otto, et al.
Publicado: (2010)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
por: Jackson, AGA, et al.
Publicado: (2010)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals
por: Cevik, Muge, et al.
Publicado: (2012)

Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from “Integriamoci”, a Pilot Pharmacokinetic Study
por: Avataneo, Valeria, et al.
Publicado: (2022)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
por: Zhang, Xue, et al.
Publicado: (2019)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

Moderating and Mediating Effects of Resilience Together with Neuroticism on Depressive Symptoms in Adult Volunteers
por: Ito, Shunichiro, et al.
Publicado: (2022)

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
por: Walimbwa, Stephen I., et al.
Publicado: (2021)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Long-Term Safety from the Raltegravir Clinical Development Program
por: Teppler, Hedy, et al.
Publicado: (2011)

Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010)

Micronucleated Erythrocytes in Newborn Rats Exposed to Raltegravir Placental Transfer
por: Torres-Mendoza, Blanca Miriam, et al.
Publicado: (2014)

Long-term efficacy and safety of raltegravir in the management of HIV infection
por: Liedtke, Michelle D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8cn6nebt6bmeu5ske6g98o0s1f